Flag of the European Union EU Clinical Trials Register Help

Clinical trials for DNA viruses

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    51 result(s) found for: DNA viruses. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2020-000685-42 Sponsor Protocol Number: 2DR-study Start Date*: 2020-04-30
    Sponsor Name:Ghent University Hospital
    Full Title: Virological and immunological assessment in HIV positive participants on 2DR versus 3DR in a prospective randomized controlled switch trial.
    Medical condition: human immunodeficiency viruses (HIV)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2013-003535-30 Sponsor Protocol Number: 200147 Start Date*: 2015-10-13
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase III, double blind, randomized, comparative study of the safety and immunogenicity of GSK Biologicals’ Varilrix HSA-free varicella vaccine and Varilrix™ given as a 2 dose course in the secon...
    Medical condition: Vaccinating Healthy volunteers (Active immunization against varicella virus disease of healthy children in their second year of life).
    Disease: Version SOC Term Classification Code Term Level
    19.0 10042613 - Surgical and medical procedures 10069613 Varicella immunisation PT
    19.0 10042613 - Surgical and medical procedures 10069628 Varicella immunization LLT
    19.0 100000004848 10063315 Varicella zoster virus DNA test positive LLT
    19.0 10021881 - Infections and infestations 10046983 Varicella zoster LLT
    19.0 10021881 - Infections and infestations 10046980 Varicella PT
    19.0 100000004858 10050331 Varicella-like rash LLT
    19.0 100000004848 10063144 Varicella zoster virus serology positive LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002732-70 Sponsor Protocol Number: YV25718 Start Date*: 2012-02-09
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Phase IIIb Parallel Group, Open Label Study of Pegylated Interferon alfa-2a Monotherapy (PEG-IFN, Ro 25-8310) Compared to Untreated Control in Children with HBeAg Positive Chronic Hepatitis B in ...
    Medical condition: Treatment of HBeAg positive chronic hepatitis B (CHB) in children.
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004848 10052552 Hepatitis B virus LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) DE (Completed) PL (Completed) IT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2008-005976-28 Sponsor Protocol Number: ETV-after-HBV-related-LTx Start Date*: 2009-08-19
    Sponsor Name:Hannover Medical School
    Full Title: Prevention of HBV reinfection after liver transplantation using entecavir monotherapy after short-term HBIg administration: A pilot study Version 1.2 2008-09-11 Amendment 2 2009-07-07
    Medical condition: chronic hepatitis B
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052552 Hepatitis B virus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-000620-26 Sponsor Protocol Number: MK-3682B-034 Start Date*: 2016-11-03
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase II/III, Open-label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-3682B (MK-3682 + Grazoprevir + MK-8408 Fixed Dose Combination) in Subjects with Chronic H...
    Medical condition: Chronic Hepatitis C Infected Patient
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004848 10019183 HCV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-012591-27 Sponsor Protocol Number: VAC037 Start Date*: 2009-11-16
    Sponsor Name:University of Oxford
    Full Title: A phase I/IIa study to assess the safety and immunogenicity of new malaria vaccine candidates AdCh63 MSP1 alone and with MVA MSP1
    Medical condition: Plasmodium Falciparum Malaria
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-005477-24 Sponsor Protocol Number: VAC045 Start Date*: 2012-02-28
    Sponsor Name:University of Oxford
    Full Title: A Phase I/IIa Sporozoite Challenge Study to Assess the Protective Efficacy of Two Prime-boost Malaria Vaccine Candidates: ChAd63 and MVA encoding ME-TRAP and the same Viral Vectors encoding CS
    Medical condition: Plasmodium falciparum infection
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-000684-16 Sponsor Protocol Number: 03MI10 Start Date*: 2010-01-21
    Sponsor Name:Great Ormond Street Hospital NHS Trust / University College London - Institute of Child Health
    Full Title: Gene therapy for SCID-X1 using a self-inactivating (SIN) gammaretroviral vector.
    Medical condition: X-Linked severe combined Immunodeficiency (SCID-X1)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010099 Combined immunodeficiency LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-017282-35 Sponsor Protocol Number: 113617 Start Date*: 2010-07-07
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IIIb, open, multi-centre gynaecological extension study for the follow-up of a subset of HPV-015 study subjects
    Medical condition: GSK Biologicals' HPV-16/18 L1 VLP AS04 vaccine is indicated in females from 10 years of age onwards for the prevention of pre-malignant cervical lesions and cervical cancer causally related to Hum...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed) NL (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2006-005692-18 Sponsor Protocol Number: 1263-300 Start Date*: 2007-07-24
    Sponsor Name:ViroPharma Incorporated
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF PROPHYLACTIC USE OF MARIBAVIR FOR THE PREVENTION OF CYTOMEGALOVIRUS DISEASE IN RECIPIENTS OF ALLOGENEIC STE...
    Medical condition: Main purpose is to assess the efficacy and safety of prophylactic use of Maribavir to prevent cytomegalovirus disease in recipients of allogeneic stem cell transplants.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10009701 CMV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) BE (Completed) FR (Completed) GB (Prematurely Ended) DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-004212-64 Sponsor Protocol Number: IMC-I109V-101 Start Date*: 2020-08-12
    Sponsor Name:Immunocore Ltd
    Full Title: An Open-label Study Evaluating the Safety, Antiviral Activity, and Pharmacokinetics of IMC-I109V in HLA-A*02:01 Positive Patients with Chronic HBV who are Non-Cirrhotic, Hepatitis B e Antigen-nega...
    Medical condition: chronic hepatitis B virus (HBV) infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004848 10019182 HBV LLT
    20.0 100000004848 10019743 Hepatitis B virus (HBV) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) PL (Prematurely Ended) RO (Completed) DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-004729-16 Sponsor Protocol Number: 1263-301 Start Date*: 2008-01-25
    Sponsor Name:ViroPharma Incorporated
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF PROPHYLACTIC USE OF MARIBAVIR VERSUS ORAL GANCICLOVIR FOR THE PREVENTION OF CYTOMEGALOVIRUS DISEASE IN RECE...
    Medical condition: Main purpose is to assess the efficacy and safety of prophylactic use of oral Maribavir versus oral Ganciclovir to prevent cytomegalovirus disease in recipients of orthotopic liver transplants at h...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009701 CMV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) FR (Completed) GB (Prematurely Ended) AT (Completed) DE (Completed) BE (Completed) ES (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-003858-25 Sponsor Protocol Number: MK-5172-052 Start Date*: 2014-03-10
    Sponsor Name:Merck Sharp & Dohme Corp. a subsidiary of Merck & Co., Inc.
    Full Title: A Phase II/III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects with Chronic Hepatitis C Virus Infection and Chronic Kidney D...
    Medical condition: Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004848 10019183 HCV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) ES (Completed) SE (Completed) EE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-004876-23 Sponsor Protocol Number: M16-133 Start Date*: 2017-09-13
    Sponsor Name:AbbVie Deutschland
    Full Title: A Single Arm, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Glecaprevir(GLE)/Pibrentasvir(PIB) in Treatment Naïve Adults with Chronic Hepatitis C Virus (HCV) Genotypes 1 – 6 ...
    Medical condition: Chronic Hepatitis C infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000074171 10019751 Hepatitis C virus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) DE (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2007-001731-55 Sponsor Protocol Number: 106636 Start Date*: 2007-08-09
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III/IV, community-randomized, controlled study to evaluate the effectiveness of two vaccination strategies using GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine in reducing the p...
    Medical condition: For the prevention of high-grade cervical intraepithelial neoplasia (CIN grades 2 and 3) and cervical cancer causally related to human papillomavirus (HPV) types 16 and 18.
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10008230 Cervix neoplasms malignant HLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2014-000343-32 Sponsor Protocol Number: 5172-062 Start Date*: 2014-05-27
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,
    Full Title: A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naïve Subjects with Chronic HCV GT1, GT4, and GT6 Infection who are...
    Medical condition: Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004848 10019751 Hepatitis C virus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) NL (Completed) GB (Completed) RO (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-018341-56 Sponsor Protocol Number: VAC039 Start Date*: 2010-05-07
    Sponsor Name:University of Oxford
    Full Title: A phase I/IIa sporozoite challenge study to assess the safety, immunogenicity and protective efficacy of new malaria vaccine candidates; AdCh63 AMA1, MVA AMA1, AdCh63 MSP1, MVA MSP1, AdCh63 ME-TRAP...
    Medical condition: Malaria (plasmodium falciparum)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-002713-17 Sponsor Protocol Number: GA42469 Start Date*: 2020-07-13
    Sponsor Name:Genentech, Inc.
    Full Title: A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MSTT1041A OR UTTR1147A IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA
    Medical condition: Severe coronavirus disease 2019 (COVID-19) pneumonia
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084383 Novel COVID-19-infected pneumonia LLT
    23.0 100000004862 10084270 SARS-CoV-2 acute respiratory disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-002828-33 Sponsor Protocol Number: ICRC-ICIT-01 Start Date*: 2012-10-10
    Sponsor Name:Fakultní nemocnice u sv. Anny v Brně
    Full Title: RANDOMIZED, MULTICENTRIC STUDY COMPARING THE EFFECT OF TWO REGIMENS OF COMBINED IMMUNOSUPPRESIVE THERAPY IN THE TREATMENT OF INFLAMMATORY CARDIOMYOPATHY CZECH-ICIT (CZECH INFLAMMATORY CARDIOMYOPATH...
    Medical condition: Patients with endomyocardial biopsy (EMB) proven inflammatory cardiomyopathy (ICM) defined by EMB established presence of myocardial inflammation and absence of cardiotropic infectious agents estab...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-000672-25 Sponsor Protocol Number: MK-5172-059 Start Date*: 2014-12-31
    Sponsor Name:Merck Sharp & Dohme Copr., a subsidary of Merck & Co.
    Full Title: A Phase II/III Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects with Chronic Hepatitis C Virus Infection with Advanced Cirrhosis and Chi...
    Medical condition: Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004848 10019751 Hepatitis C virus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Prematurely Ended) ES (Prematurely Ended) NL (Completed) EE (Completed) PL (Completed) IT (Prematurely Ended) GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 15:18:03 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA